Person:
Fernández Gómez, Francisco José

Profile Picture
Name
Fernández Gómez, Francisco José
publication.page.department
Universidad de Murcia. Departamento de Atención Sociosanitaria
Repository logoRepository logoRepository logo

Filters

2023 - 20243
3
3
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Open Access
    Editorial: Exploring prevention strategies and treatment in addictive disorders.
    (2024-07-04) Montagud-Romero, Sandra; Gómez Murcia, Victoria; Fernández Gómez, Francisco José; Núñez Parra, Cristina; Farmacología
  • Thumbnail Image
    Publication
    Open Access
    TRAP-induced platelet reactivity is inhibited by omega-3 fatty acid-derived prostaglandin E3 (PGE3)
    (MDPI, 2024-12-16) Osete Albaladejo, José Miguel; García Candel, Faustino; Fernández Gómez, Francisco José; Blanquer Blanquer, Miguel; Marín Atucha, Noemí; García-Estañ López, Joaquín; Iyú Espinosa, David; Fisiología; Facultades de la UMU::Facultad de Medicina
    Background: Prostaglandins are naturally occurring local mediators that can participate in the modulation of the cardiovascular system through their interaction with Gs/Gi-coupled receptors in different tissues and cells, including platelets. Thrombin is one of the most important factors that regulates platelet reactivity and coagulation. Clinical trials have consistently shown that omega-3 fatty acid supplementation lowers the risk for cardiovascular mortality and morbidity. Since omega-3 fatty acids are the main precursors of PGE3 in vivo, it would be relevant to investigate the effects of PGE3 on Thrombin Receptor Activating Peptide (TRAP-6)-induced platelet reactivity to determine the receptors and possible mechanisms of action of these compounds. Methods: We have measured platelet aggregation, P-selectin expression, and vasodilator-stimulated phosphoprotein (VASP) phosphorylation to evaluate platelet reactivity induced by TRAP-6 to determine the effects of PGE3 on platelet function. Results: We assessed the ability of DG-041, a selective prostanoid EP3 receptor antagonist, and of ONO-AE3-208, a selective prostanoid EP4 receptor antagonist, to modify the effects of PGE3. PGE3 inhibited TRAP-6-induced platelet aggregation and activation. This inhibition was enhanced in the presence of a Gi-coupled EP3 receptor antagonist and abolished in the presence of a Gs-coupled EP4 receptor antagonist. The effects of PGE3 were directly related to changes in cAMP, assessed by VASP phosphorylation. Conclusions: The general effects of PGE3 on human platelet reactivity are the consequence of a balance between activatory and inhibitory effects at receptors that have contrary effects on adenylate cyclase. These results indicate a potential mechanism by which omega-3 fatty acids underlie cardioprotective effects.
  • Thumbnail Image
    Publication
    Open Access
    Effect of Pharmaceutical Intervention in Pharmacologically Treated Hypertensive Patients-A Cluster-Randomized Clinical Trial: AFPRES-CLM Study.
    (2023-10-11) Luque Del Moral, Raúl; Gastelurrutia, Miguel A; Martinez-Martinez, Fernando; Jacomé, Julio A; Dago, Ana; Suarez, Blanca; Fikri-Benbrahim, Narjis; Martí, Mercé; Núñez Parra, Cristina; Sierra Alarcón, Sandra; Fernández Gómez, Francisco José; Farmacología
    Background: Evaluate the effect of a community pharmaceutical intervention on the control of blood pressure in hypertensive patients treated pharmacologically. Methods: A cluster-randomized clinical trial of 6 months was carried out. It was conducted in the Autonomous Community of Castilla-La Mancha (Spain). Sixty-three community pharmacies and 347 patients completed the study. Intervention patients received the community pharmaceutical intervention based on a protocol that addresses the individual needs of each patient related to the control of their blood pressure, which included Health Education, Pharmacotherapy Follow-up and 24 h Ambulatory Blood Pressure Measurement. Control patients received usual care in the community pharmacy. Results: The pharmaceutical intervention resulted in better control of blood pressure (85.8% vs. 66.3% p < 0.001), lower use of emergencies (p = 0.002) and improvement trends in the physical components of quality of life, measured by SF-36 questionnaire, after 6 months of pharmaceutical intervention. No significant changes were observed for any of these variables in the control group. There were also detected 354 negative medication-related outcomes that were satisfactorily resolved in a 74.9% of the cases and 330 healthcare education interventions and 29 Ambulatory Blood Pressure Monitorings were performed in order to increase adherence to pharmacological treatment and minimize Negative Outcomes associated with Medication and prevent medication-related problems. Conclusions: Community pharmaceutical intervention can increase hypertensive patients with controlled blood pressure, after 6 months, compared with usual care.
Ir a Estadísticas